Clinical Trial

Daridorexant for Alcohol Use Disorder

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study will test whether the dual orexin receptor antagonist (DORA) daridorexant reduces alcohol craving and use and improves total sleep time among patients with co-occurring alcohol use disorder and sleep disturbance. The study will assess the role of the orexin system in modulating alcohol craving and use in a real-world treatment setting.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-04-08.
Trial Details
NCT Number NCT07532252
Lead Sponsor Johns Hopkins University
Collaborators: Idorsia Pharmaceuticals Ltd., National Institutes of Health (NIH)
Conditions Alcohol Use Disorder
Enrollment 150 participants
Start Date 2027-01-01
Primary Completion 2030-08-01 (estimated)
Study Completion 2031-02-01 (estimated)
Updated on ClinicalTrials.gov 2026-04-20